Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dyslipidemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H1 2015', provides an overview of the Dyslipidemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Dyslipidemia Overview 9 Therapeutics Development 10 Pipeline Products for Dyslipidemia - Overview 10 Pipeline Products for Dyslipidemia - Comparative Analysis 11 Dyslipidemia - Therapeutics under Development by Companies 12 Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 16 Dyslipidemia - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Dyslipidemia - Products under Development by Companies 20 Dyslipidemia - Products under Investigation by Universities/Institutes 24 Dyslipidemia - Companies Involved in Therapeutics Development 25 Amgen Inc. 25 Arisaph Pharmaceuticals, Inc. 26 AstraZeneca PLC 27 Biocon Limited 28 Cadila Pharmaceuticals Ltd. 29 Cerenis Therapeutics Holding SA 30 Chong Kun Dang Pharmaceutical Corp. 31 CymaBay Therapeutics, Inc. 32 Daiichi Sankyo Company, Limited 33 Debiopharm International S.A. 34 Dezima Pharma BV 35 Dr. Reddy's Laboratories Limited 36 Genfit SA 37 GlaxoSmithKline plc 38 Hanmi Pharmaceuticals, Co. Ltd. 39 High Point Pharmaceuticals, LLC 40 Intas Pharmaceuticals Ltd. 41 Jenrin Discovery, Inc. 42 JW Pharmaceutical Corporation 43 Kissei Pharmaceutical Co., Ltd. 44 Kotobuki Pharmaceutical Co., Ltd. 45 Kowa Company, Ltd. 46 Kymab Limited 47 Lipicard Technologies Limited 48 Merck & Co., Inc. 49 Nippon Chemiphar Co., Ltd. 50 Novartis AG 51 Pfizer Inc. 52 Pharmena SA 53 Piramal Enterprises Limited 54 Reviva Pharmaceuticals Inc. 55 Sanofi 56 Takeda Pharmaceutical Company Limited 57 Torrent Pharmaceuticals Limited 58 Zydus Cadila Healthcare Limited 59 Dyslipidemia - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 64 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 (ezetimibe + rosuvastatin calcium) - Drug Profile 70 (niacin + aspirin) - Drug Profile 71 (pitavastatin + valsartan) - Drug Profile 72 (rosuvastatin calcium + ezetimibe) - Drug Profile 73 (statin + niacin + aspirin) - Drug Profile 74 4655-K09 - Drug Profile 75 anacetrapib - Drug Profile 76 ARI-3037MO - Drug Profile 78 AZ-12260493 - Drug Profile 80 BioE-1115 - Drug Profile 81 bococizumab - Drug Profile 82 BSN-852 - Drug Profile 83 C-24 - Drug Profile 84 C-3 - Drug Profile 85 Centatin - Drug Profile 86 CKD-519 - Drug Profile 87 Debio-0930B - Drug Profile 88 DEZ-001 - Drug Profile 89 DF-461 - Drug Profile 90 DGAT-1 - Drug Profile 91 DRL-17822 - Drug Profile 92 evolocumab - Drug Profile 93 GFT-505 - Drug Profile 96 GSK-2041706 - Drug Profile 99 HCP-1105 - Drug Profile 100 HCP-1305 - Drug Profile 101 HDL Receptor Enhancer - Drug Profile 102 HPP-593 - Drug Profile 103 INSUPR-001 - Drug Profile 104 JD-5037 - Drug Profile 105 K-312 - Drug Profile 106 K-877 - Drug Profile 107 KT6-971 - Drug Profile 108 KTA-439 - Drug Profile 109 KY-1020 - Drug Profile 110 LP-071 - Drug Profile 111 LT-5421 - Drug Profile 112 LT-5423 - Drug Profile 113 MAT-9001 - Drug Profile 114 MBX-8025 - Drug Profile 115 MGL-3196 - Drug Profile 117 NC-2400 - Drug Profile 119 ND-630 - Drug Profile 120 ND-654 - Drug Profile 121 P-7435 - Drug Profile 122 Peroxibrate - Drug Profile 123 pitavastatin CR - Drug Profile 124 Recombinant ApoE4 for Dyslipidemia - Drug Profile 125 RP-17000 - Drug Profile 126 Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 127 Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes - Drug Profile 128 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 129 Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia - Drug Profile 130 Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 131 Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 132 Small Molecules to Inhibit DGAT-1 for Metabolic Disorders - Drug Profile 133 Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 134 SPX-100 - Drug Profile 135 SPX-8522876 - Drug Profile 136 Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 137 TAP-311 - Drug Profile 138 TRC-210258 - Drug Profile 139 TRIA-662 - Drug Profile 140 VK-0214 - Drug Profile 142 ZLN-005 - Drug Profile 143 ZLN-024 - Drug Profile 144 ZYH-7 - Drug Profile 145 ZYT-1 - Drug Profile 146 Dyslipidemia - Recent Pipeline Updates 147 Dyslipidemia - Dormant Projects 168 Dyslipidemia - Discontinued Products 175 Dyslipidemia - Product Development Milestones 180 Featured News & Press Releases 180 Appendix 194 Methodology 194 Coverage 194 Secondary Research 194 Primary Research 194 Expert Panel Validation 194 Contact Us 195 Disclaimer 195
List of Tables Number of Products under Development for Dyslipidemia, H1 2015 15 Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2015 16 Number of Products under Development by Companies, H1 2015 18 Number of Products under Development by Companies, H1 2015 (Contd..1) 19 Number of Products under Development by Companies, H1 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2015 29 Dyslipidemia - Pipeline by Amgen Inc., H1 2015 30 Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 31 Dyslipidemia - Pipeline by AstraZeneca PLC, H1 2015 32 Dyslipidemia - Pipeline by Biocon Limited, H1 2015 33 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2015 34 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2015 35 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 36 Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2015 37 Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 38 Dyslipidemia - Pipeline by Debiopharm International S.A., H1 2015 39 Dyslipidemia - Pipeline by Dezima Pharma BV , H1 2015 40 Dyslipidemia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 41 Dyslipidemia - Pipeline by Genfit SA, H1 2015 42 Dyslipidemia - Pipeline by GlaxoSmithKline plc, H1 2015 43 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44 Dyslipidemia - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 45 Dyslipidemia - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 46 Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2015 47 Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H1 2015 48 Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 49 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2015 50 Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2015 51 Dyslipidemia - Pipeline by Kymab Limited, H1 2015 52 Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2015 53 Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2015 54 Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 55 Dyslipidemia - Pipeline by Novartis AG, H1 2015 56 Dyslipidemia - Pipeline by Pfizer Inc., H1 2015 57 Dyslipidemia - Pipeline by Pharmena SA, H1 2015 58 Dyslipidemia - Pipeline by Piramal Enterprises Limited, H1 2015 59 Dyslipidemia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 60 Dyslipidemia - Pipeline by Sanofi, H1 2015 61 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 63 Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 64 Assessment by Monotherapy Products, H1 2015 65 Assessment by Combination Products, H1 2015 66 Number of Products by Stage and Target, H1 2015 68 Number of Products by Stage and Mechanism of Action, H1 2015 70 Number of Products by Stage and Route of Administration, H1 2015 72 Number of Products by Stage and Molecule Type, H1 2015 74 Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2015 152 Dyslipidemia - Dormant Projects, H1 2015 173 Dyslipidemia - Dormant Projects (Contd..1), H1 2015 174 Dyslipidemia - Dormant Projects (Contd..2), H1 2015 175 Dyslipidemia - Dormant Projects (Contd..3), H1 2015 176 Dyslipidemia - Dormant Projects (Contd..4), H1 2015 177 Dyslipidemia - Dormant Projects (Contd..5), H1 2015 178 Dyslipidemia - Dormant Projects (Contd..6), H1 2015 179 Dyslipidemia - Discontinued Products, H1 2015 180 Dyslipidemia - Discontinued Products (Contd..1), H1 2015 181 Dyslipidemia - Discontinued Products (Contd..2), H1 2015 182 Dyslipidemia - Discontinued Products (Contd..3), H1 2015 183 Dyslipidemia - Discontinued Products (Contd..4), H1 2015 184
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
